ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial

NCT07264894 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)

Interventions

DRUG: ZSDT regimen

Sponsor

Zhengzhou University